Reunion Neuroscience
3 known investors
Reunion develops serotonergic psychedelic therapies for mental health conditions, targeting postpartum depression, adjustment disorder, and generalized anxiety disorder. The company is advancing luvesilocin, a clinical-stage drug candidate and patented prodrug designed to provide fast-acting antidepressive effects.
BiotechDigital HealthMental Health
Founders & leadership
SV
Sahil V. KirpekarPresident and CEO
Investors · 3
In the news
- Reunion Neuroscience Inc. announced that it has received $133 million in funding from a group of investors | MarketScreenermarketscreener.com · 2025
- Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)finance.yahoo.com · 2025
- Reunion Neuroscience expands Series A to $133m after positive trial milestones - Pharmaceutical Technologypharmaceutical-technology.com · 2025
- Reunion Neuroscience Raises Post Pardum Depression at MMH Forumclinicaltrialvanguard.com · 2025
- Reunion Neuroscience raises $103 million for a psychedelic to treat depressioncen.acs.org · 2024
- Reunion Neuroscience - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2022